Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193583
Status:
COMPLETED
Last Update Posted:
2011-05-04
First Post:
2005-09-12
Brief Title:
Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory andor Advanced Solid Tumors
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
A Phase I Study of Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Patients With Refractory andor Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this phase I study we will characterize the safety tolerability maximum tolerated dose and dose-limiting toxicity of weekly bolus topotecan when administered in combination with two different dosing schedules of carboplatin We will also evaluate any antitumor activity of these combination regimens
Detailed Description:
Upon determination of eligibility patients will be receive
Topotecan Carboplatin
In order to determine the most appropriate dosing regimen to progress into future phase II trials two different dosing schedules of topotecan and carboplatin will be utilized ARM I and ARM II Patients will be accrued to both treatment arms simultaneously
Topotecan Carboplatin
In order to determine the most appropriate dosing regimen to progress into future phase II trials two different dosing schedules of topotecan and carboplatin will be utilized ARM I and ARM II Patients will be accrued to both treatment arms simultaneously
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 104864-707 | None | None | None |